- Home
- SONO vs ZLAB Comparison
SONO vs ZLAB Comparison
Compare SONO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- ZLAB
- Stock Information
- Founded
- SONO 2002
- ZLAB 2013
- Country
- SONO United States
- ZLAB China
- Employees
- SONO N/A
- ZLAB N/A
- Industry
- SONO Consumer Electronics/Video Chains
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- ZLAB Health Care
- Exchange
- SONO Nasdaq
- ZLAB Nasdaq
- Market Cap
- SONO 1.4B
- ZLAB 1.8B
- IPO Year
- SONO 2018
- ZLAB 2017
- Fundamental
- Price
- SONO $12.96
- ZLAB $31.38
- Analyst Decision
- SONO Hold
- ZLAB Strong Buy
- Analyst Count
- SONO 3
- ZLAB 4
- Target Price
- SONO $15.67
- ZLAB $52.50
- AVG Volume (30 Days)
- SONO 1.3M
- ZLAB 976.3K
- Earning Date
- SONO 11-13-2024
- ZLAB 11-12-2024
- Dividend Yield
- SONO N/A
- ZLAB N/A
- EPS Growth
- SONO N/A
- ZLAB N/A
- EPS
- SONO N/A
- ZLAB N/A
- Revenue
- SONO $1,567,823,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- SONO N/A
- ZLAB $48.34
- Revenue Next Year
- SONO N/A
- ZLAB $47.12
- P/E Ratio
- SONO N/A
- ZLAB N/A
- Revenue Growth
- SONO N/A
- ZLAB 28.16
- 52 Week Low
- SONO $10.10
- ZLAB $13.48
- 52 Week High
- SONO $19.76
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- SONO 60.67
- ZLAB 70.41
- Support Level
- SONO $12.76
- ZLAB $31.52
- Resistance Level
- SONO $13.19
- ZLAB $36.60
- Average True Range (ATR)
- SONO 0.36
- ZLAB 1.36
- MACD
- SONO 0.06
- ZLAB 0.34
- Stochastic Oscillator
- SONO 93.84
- ZLAB 58.60
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa, and the Asia Pacific. Generating a majority of its revenue from the Americas.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.